The FDA’s decision to delay MDMA-assisted therapy highlights growing caution in psychedelic research; however, VA studies aim to clarify efficacy and safety for veterans, addressing FDA concerns.
Shereef Elnahal expressed disappointment following the FDA's decision, noting veterans believe MDMA therapy could be transformative. The VA's research is designed to answer FDA's safety queries.
VA-supported research involves veterans with PTSD and alcohol use disorder, using a design that mirrors the controversial Lykos study while addressing concerns over placebo effects.
The recent delay does not signify an end to psychedelic therapy advancement, with experts expressing optimism that ongoing studies could reshape FDA's perception of these treatments.
Collection
[
|
...
]